Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Edit RemákR J Motzer

Abstract

To assess the cost effectiveness and cost utility of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and interleukin-2 (IL-2) from a US societal perspective. A Markov model was developed to simulate disease progression and to determine progression-free survival, total life-years (LYs), and quality-adjusted life-years (QALYs) gained. Model parameters were derived from the pivotal trial of sunitinib, published literature, government sources, and clinical experts' opinions. The model included trial-based adverse events (AEs). Costs of drug treatment, routine follow-up, AEs, disease progression, and best supportive care (BSC) of terminally ill patients were included. Results were tested using probabilistic and deterministic sensitivity analyses. Treatment with sunitinib is associated with a gain in progression-free years of 0.41 and 0.35 over IFN-alpha and IL-2. The estimated gains over IFN-alpha were 0.11 LYs and 0.14 QALYs, and over IL-2 were 0.24 LYs and 0.20 QALYs. Both IFN-alpha and sunitinib treatments dominate IL-2 treatment; the incremental cost-effectiveness ratio of sunitinib versus IFN-alpha was $18,611 per progression-free year gained and $67...Continue Reading

References

Jan 1, 1994·Medical Decision Making : an International Journal of the Society for Medical Decision Making·D K Miller, S M Homan
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Apr 18, 2001·Current Opinion in Oncology·P A Godley, M Taylor
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Jan 28, 2005·The Cochrane Database of Systematic Reviews·C CoppinT Wilt
Apr 22, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andrew Briggs
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerBrian I Rini
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Apr 6, 2007·European Urology·Börje LjungbergUNKNOWN European Association of Urology Guideline Group for renal cell carcinoma

❮ Previous
Next ❯

Citations

Dec 1, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E Calvo AllerS Díaz Cerezo
Oct 22, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Germaine WongJonathan C Craig
Oct 22, 2008·Expert Review of Anticancer Therapy·Thomas E Hutson
May 14, 2014·PharmacoEconomics·Fabrice SmieliauskasYa-Chen Tina Shih
Sep 13, 2011·Urologic Oncology·Nicholas J Hellenthal, Carlos E Bermejo
Dec 17, 2008·Urologic Oncology·Christopher S SaigalMatthias Schonlau
Dec 2, 2011·Journal of Cellular and Molecular Medicine·Muhammad A SirajNicolae Ghinea
Dec 27, 2011·Expert Opinion on Pharmacotherapy·Eduard VrdoljakLaszlo Torday
Sep 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Roman CascianoLou Garrison
Jun 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Peter S GrimisonMartin R Stockler
Jun 6, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Peter S GrimisonMartin R Stockler
Jun 22, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Isabelle Chabot, Angela Rocchi
Oct 7, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin HoyleKen Stein
Oct 7, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin HoyleKen Stein
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sabrina Trippoli, Andrea Messori
Mar 11, 2010·Expert Review of Anticancer Therapy·Bernard Escudier
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Timo T Purmonen
Jul 23, 2020·Current Medical Research and Opinion·Arielle G BensimonDaniel M Geynisman
Nov 2, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kazuki TomuraTadanori Sasaki
Sep 17, 2017·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·S de GrootC A Uyl-de Groot

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved